Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Infant formula GMPs

This article was originally published in The Tan Sheet

Executive Summary

FDA is extending the comment period on its proposed infant formula GMPs and quality control procedures for 60 days to Aug. 26, agency announces in 1June 27 Federal Register notice. Action follows request from International Formula Council citing need for more time to prepare comments (2"The Tan Sheet" May 26, 2003, In Brief)...

You may also be interested in...



Infant formula GMPs

Comment period on proposed infant formula GMPs and quality control procedures should be extended 60 days to Aug. 26, International Formula Council says in May 6 comments to FDA. Group is requesting extension "on behalf of all U.S. manufacturers of infant formula," noting "appropriateness of granting this extension is further underscored by the fact that only a few responders...are affected directly and their comments are anticipated to be comprehensive and in-depth and to require significant preparation time." FDA reopened comment period on the proposed rule, which was issued in 1996, in April (1"The Tan Sheet" May 5, 2003, In Brief)...

QUOTED. 28 January 2020. Steven Falowski.

Abbott is encouraged by results from two studies of its Proclaim XR neurostimulation system for chronic pain, presented at the annual North American Neuromodulation Society (NANS) meeting in Las Vegas. See what Steven Falowski of Neurosurgical Associates of Lancester in Pennsylvania said about it here.

Japan Phase III Failure To End Mono Opdivo Hopes In Ovarian Cancer?

While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.

Topics

UsernamePublicRestriction

Register

PS095633

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel